Entire cohort | Patients with positive SLN | Patients with negative SLN | p | |
---|---|---|---|---|
Number | 203* | 44/197* (22%) | 153/197* (78%) | |
Sex | 0.2706 | |||
Men | 100 (49.3%) | 18 (41%) | 76 (50%) | |
Women | 103 (50.7%) | 26 (59%) | 77 (50%) | |
Mean age (+/− SD) | 55.8 +/−15.6 | 52.0 +/−17.4 | 56.6 +/−15.0 | 0.0864 |
Localization | 0.1483 | |||
Trunk | 74 (36.5%) | 17 (38.6%) | 54 (35.3%) | |
Upper limb | 39 (19.2%) | 3 (6.8%) | 33 (21.6%) | |
Lower limb | 63 (31.0%) | 16 (36.4%) | 47 (30.7%) | |
Hands and feet | 27 (13.3%) | 8 (18.2%) | 19 (12.4%) | |
Type | 0.6978 | |||
Superficial | 115 (56.6%) | 25 (56.8%) | 86 (56.2%) | |
Nodular | 39 (19.2%) | 6 (13.6%) | 31 (20.3%) | |
Acral | 17 (8.4%) | 4 (9.1%) | 13 (8.5%) | |
Other | 32 (15.8%) | 9 (20.5%) | 23 (15.0%) | |
Mean tumor thickness (range) | 1.88 (0.4 - 10.1) | 2.8 (1.2 - 10) | 1.6 (0.4 - 10.1) | 0.0289 |
T stage[2] | 0.0172 | |||
T1 | 10 (4.9%) | 0 | 10 (6.5%) | |
T2 | 101 (49.7%) | 15 (34.1%) | 83 (54.3%) | |
T3 | 55 (27.1%) | 17 (38.6%) | 36 (23.5%) | |
T4 | 33 (16.3%) | 11 (25.0%) | 21 (13.7%) | |
Incalculable1 | 4 (2.0%) | 1 (2.3%) | 3 (2.0%) | |
Clark level | 0.3677 | |||
I | 1 (0.5%) | 0 | 1 (0.7%) | |
II | 10 (4.9%) | 2 (4.5%) | 8 (5.2%) | |
III | 56 (27.6%) | 9 (20.5%) | 46 (30.1%) | |
IV | 100 (49.3%) | 26 (59.1%) | 70 (45.7%) | |
V | 12 (5.9%) | 4 (9.1%) | 7 (4.6%) | |
Unknown | 24 (11.8%) | 3 (6.8%) | 21 (13.7%) | |
Ulceration | 0.0080 | |||
Yes | 60 (29.6%) | 21 (47.7%) | 37 (24.2%) | |
No | 131 (64.5%) | 20 (45.5%) | 107 (69.9%) | |
Unknown | 12 (5.9%) | 3 (6.8%) | 9 (5.9%) |